Anti-Outer membrane protein C antibodies in colorectal neoplasia
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
26612659
DOI
10.1007/s12223-015-0437-4
PII: 10.1007/s12223-015-0437-4
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- ELISA MeSH
- kolorektální nádory patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- poriny imunologie MeSH
- protilátky bakteriální krev MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- OmpC protein MeSH Prohlížeč
- poriny MeSH
- protilátky bakteriální MeSH
Sporadic colorectal cancer (CRC) represents an enormous problem worldwide. Large intestinal microbiota play an important role in the colorectal carcinogenesis. The aim of the study was to investigate anti-Outer membrane protein C (anti-OmpC) antibodies, aimed at porin C, which is embedded in the outer membrane of gram-negative bacteria, in patients with colorectal adenoma (CRA), CRC and controls. The study included 22 patients with CRA (11 men, 11 women, aged 26-79, mean 65 ± 12), 11 patients with CRC (9 men, 2 women, aged 50-83, mean 66 ± 11) and 45 controls, blood donors (24 men, 21 women, aged 20-58, mean 38 ± 10). Serum anti-OmpC antibodies were investigated by means of ELISA. Values of 0-20 U/mL were considered to be negative; values >25 U/mL were assessed as positive. A total of 9/11 (82 %) patients with CRC had positive anti-OmpC antibodies. Anti-OmpC antibodies were negative or grey-zone in 37/45 (82 %) controls. Serum anti-OmpC were found to be significantly higher in patients with CRC (median 42.4, interquartile range (IQR) 22.2) compared to controls (median 18.3, IQR 12.4), p < 0.001. No statistically significant difference in anti-OmpC was found between controls (median 18.3, IQR 12.4) and CRA patients (median 17.7, IQR 16.5), p = 0.326. Anti-OmpC were significantly higher in patients with CRC (median 42.4, IQR 22.2) compared to patients with CRA (median 17.7, IQR 16.5), p = 0.011. Positivity of anti-OmpC antibodies was found in patients with CRC, which supports the contribution of gram-negative large intestinal microbiota to the pathogenesis of CRC.
Zobrazit více v PubMed
Int J Cancer. 2015 Mar 1;136(5):E359-86 PubMed
Future Microbiol. 2013 Apr;8(4):445-60 PubMed
Microbiol Mol Biol Rev. 2003 Dec;67(4):593-656 PubMed
EMBO Rep. 2006 Jul;7(7):688-93 PubMed
PLoS One. 2011;6(5):e20447 PubMed
J Microbiol Methods. 2008 Feb;72(2):124-32 PubMed
BMC Infect Dis. 2014 Dec 24;14:733 PubMed
J Biol Chem. 1994 Feb 11;269(6):3905-8 PubMed
J Lipid Res. 2006 Feb;47(2):241-59 PubMed
BMC Gastroenterol. 2014 Dec 31;14:190 PubMed
Dig Dis. 2009;27(3):206-11 PubMed
Microb Pathog. 2012 Sep;53(3-4):180-2 PubMed
Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):323-36 PubMed
Tumour Biol. 2013 Jun;34(3):1285-300 PubMed
Gastroenterology. 2004 Feb;126(2):414-24 PubMed
Cancer Res. 1975 Nov;35(11 Pt. 2):3421-6 PubMed
J Biol Chem. 1976 Apr 10;251(7):2176-8 PubMed
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11537-42 PubMed
Mol Microbiol. 2000 Jul;37(2):239-53 PubMed
Science. 2006 Aug 11;313(5788):848-51 PubMed
Infect Immun. 2000 Mar;68(3):1542-8 PubMed
Infect Immun. 2012 May;80(5):1815-22 PubMed
Am J Gastroenterol. 2004 Nov;99(11):2235-41 PubMed
Infect Immun. 2009 Nov;77(11):4696-703 PubMed
Carcinogenesis. 2007 Nov;28(11):2419-25 PubMed
Am J Gastroenterol. 2008 Mar;103(3):665-81 PubMed
Nutr Cancer. 2012;64(1):34-40 PubMed